论文部分内容阅读
目的探讨干扰素(IFN)联合CP方案(环磷酰胺+卡铂)化疗对卵巢浆液性囊腺癌Ⅲ期患者预后的影响。方法选取中国医科大学附属第一医院妇科1998年1月至2004年6月收治的79例原发性卵巢浆液性囊腺癌Ⅲ期患者,随访成功者58例,按化疗疗程数以及是否应用干扰素分成3组(Ⅰ组26例,为术后未给予化疗或CP方案化疗次数<6次;Ⅱ组14例,为术后仅接受CP方案化疗次数≥6次;Ⅲ组18例,为术后接受CP方案联合干扰素化疗次数≥6次),比较3组生存率、近期疗效(1年)的关系。结果3组患者随访1～120个月,失访21例,随访率73.42%。Ⅰ～Ⅲ组1年生存率分别为73.08%、92.86%、94.44%,3年生存率分别为19.23%、57.14%、66.67%,5年生存率分别为11.54%、35.71%、38.89%,3组患者生存率比较差异有统计学意义(P<0.05)。Ⅱ、Ⅲ组患者生存率比较差异无统计学意义(P>0.05),但近期疗效存在明显差异(P<0.05)。结论术后足够疗程CP方案或CP方案联合干扰素治疗卵巢浆液性囊腺癌可以显著提高患者生存率;联合应用干扰素化疗未能显著提高患者生存率,但可以明显提高其近期疗效。
Objective To investigate the effect of interferon (IFN) combined with CP (cyclophosphamide + carboplatin) chemotherapy on the prognosis of patients with stage Ⅲ ovarian serous cystadenocarcinoma. Methods A total of 79 patients with primary ovarian serous cystadenocarcinoma who underwent gynecology at the First Affiliated Hospital of China Medical University from January 1998 to June 2004 were enrolled in this study. Fifty-eight follow-up cases were successfully followed up according to the number of chemotherapy courses and whether the application of interference The patients were divided into 3 groups (group Ⅰ, 26 cases, no chemotherapy or CP chemotherapy after operation, the number of times less than 6 times; Ⅱ group of 14 cases, only after receiving CP regimen chemotherapy times 6 times; Ⅲ group 18 cases, After receiving CP regimen combined with interferon chemotherapy ≥ 6 times), the survival rate of 3 groups, the recent efficacy (1 year) relationship. Results The 3 groups were followed up for 1 ~ 120 months, 21 cases were lost to follow-up, the follow-up rate was 73.42%. The 1-year survival rates of group Ⅰ ~ Ⅲ were 73.08%, 92.86% and 94.44% respectively. The 3-year survival rates were 19.23%, 57.14% and 66.67%, respectively. The 5-year survival rates were 11.54%, 35.71% and 38.89%, respectively There was significant difference in survival rate between the two groups (P <0.05). There was no significant difference in survival rate between the two groups (P> 0.05), but there was significant difference in the short term efficacy (P <0.05). Conclusions Sufficient treatment of CP or CP combined with interferon in the treatment of ovarian serous cystadenocarcinoma can significantly improve the survival rate of the patients. Combined application of interferon chemotherapy can not significantly improve the survival rate of patients, but can significantly improve the short-term efficacy.